Elizabeth Gough-Gordon

A new review indicates that gabapentin may be an effective adjunct therapy for primary headache syndromes, but that there is not enough evidence to support its use as a primary treatment.

The first cohort study on the long-term safety of medical cannabis found that patients with chronic noncancer pain using cannabis daily for one year did not experience more serious adverse events (SAEs) compared to controls, although they did experience more non-serious adverse events (AEs).

Commonly used antidepressants appear to target specific neurotransmitters in the brain that regulate chronic pain and depression-like symptoms, a newly understood mechanism that could shape future treatments for nerve pain and depression.

Based on a new study published in Neurology, researchers have developed the first clinical recommendations for making diagnostic decisions regarding headaches in pregnant women.

Sharing clinical notes with patients led to improved medication adherence and recall of treatment recommendations, according to a study in The Joint Commission Journal on Quality and Patient Safety.

Although rates of opioid prescribing reached a plateau from 2006 to 2010, the co-prescribing of opioids and sedative hypnotics did not decrease over a nine-year period despite guidelines that advise against co-prescribing of these medications.

A study appearing in Neuroscience and Biobehavioral Reviews suggests that pharmacokinetics play a significant role in the risk of abuse and misuse associated with varying drugs, from nicotine to cocaine.

New research in Pediatrics suggests that children who are exposed to antibiotics could have an increased risk of newly diagnosed juvenile idiopathic arthritis (JIA), but that antibiotic use could be a marker for abnormal immunity rather than a direct cause of JIA.

A new report in the CDC’s Vital Signs outlines key findings associated with heroin use disorders, including demographics and the need for comprehensive treatment strategies.

The agency approved Zomig (zolmitriptan) Nasal Spray for use in pediatric patients aged at least 12 years.